Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality - PubMed
3 hours ago
- #Antidiabetic Medication
- #Type 2 Diabetes
- #Cardiovascular Risk
- Timely initiation of antidiabetic medication (ADM) is essential for lowering long-term cardiovascular risk in individuals meeting the diagnostic threshold for type 2 diabetes (T2D).
- The study estimated the association between ADM initiation timing (within 3, 6, or 12 months) and the risk of major adverse cardiovascular events (MACE) and all-cause mortality in newly diagnosed T2D individuals using Korean health data from 2013-2022.
- Earlier ADM initiation showed progressively lower point estimates for 3-point MACE, though not statistically significant, with ADM within 3 months yielding significant risk reduction for all-cause mortality in both relative and absolute scales.
- The findings suggest a potential cardiovascular benefit of early glycemic control, but further evaluation in larger studies is warranted due to low event counts and the observational nature of the study.